The New Frontiers in Atrial Fibrillation

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

January 6, 2010

Expiration Date:

January 6, 2012

Intended Audience:

This WebCAST has been conceived for the following audience:

• Cardiologists
• Preventive cardiologists
• Cardiovascular electrophysiologists
• Neurovascular specialists
• Vascular biologists
• Anticoagulation experts
• Heart failure specialists
• Coronary care unit (CCU) specialists and directors
• Program directors, cardiovascular medicine
• Fellows in cardiovascular medicine
• Clinical pharmacists and pharmacologists
• Pharmacy directors (cardiovascular medicine)
• Investigators and clinical trial specialists
• Cardiovascular nurses

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent educational grant from Boehringer-Ingelheim.

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 3.0 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosures:

Samuel Z. Goldhaber, MD – Program Chairman
Cardiovascular Division
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, MA

Grant/Research Support: BMS, Boehringer-Ingelheim, Eisai, Johnson and Johnson, sanofiaventis
Consultant: BMS, Boehringer-Ingelheim, Eisai, Medscape, Merck, sanofi-aventis, Vortex

Jeffrey I Weitz, MD, FRCP, FACP
Professor of Medicine and Biochemistry
McMaster University
Director, Henderson Research Center
Canada Research Chair in Thrombosis
Heart and Stroke Foundation
J.F. Mustard Chair in Cardiovascular Research
Hamilton, Ontario, Canada

Grants/Research Support: CIHR, HSFO, CFI, ORF
Speakers Bureau: Bristol-Myers Squibb, Boehringer Ingelheim, sanofi-aventis, Daiichi-Sankyo, Bayer, Pfizer, The Medicines Company, Eisai, Takeda

Jonathan L. Halperin, MD
Professor of Medicine (Cardiology)
Mount Sinai School of Medicine
Director, Clinical Cardiology Services
The Zena and Michael A. Weiner Cardiovascular Institute
The Marie-Josée and Henry R. Kravis Center for Cardiovascular Health
New York, NY

Consulting fees from the following companies involved in development of investigational drugs or devices: Astellas Pharma, U.S., Bayer HealthCare, Biotronik, Inc., Boehringer Ingelheim, Daiichi Sankyo Pharma, Johnson & Johnson, Portola Pharmaceuticals, and sanofi-aventis

Program Managers and Disclosures

Gideon Bosker, MD
Nothing to Disclose

Milo Falcon
Nothing to Disclose

Denise Leary
Nothing to Disclose

Educational Objectives:

Participants in this CME-certified WebCAST will:

• Learn about advances in oral anticoagulation based on new mechanisms involving inhibition of the coagulation cascade and possible implications for prophylaxis of arterial thromboembolism in the setting of atrial fibrillation
  
  
• Learn about the mechanisms involved in thromboembolic prevention and the rationale for identifying agents with predictable anticoagulation, in the absence of clinical monitoring.
  
  
• Learn about current ACCP, ACC, AHA, and AAN guidelines for stroke prevention in the setting of AF. Clinicians will learn about current guidelines for stroke prevention for patients with heart disease, including AF.
  
  
• Learn about novel approaches for residual risk reduction and secondary prevention of adverse thromboembolic events (stroke) in the setting of atrial fibrillation, and related conditions.
  
  
• Learn how to apply landmark clinical trials focusing on thromboembolic risk prevention in patients with ACS and atrial fibrillation.
  
  
• Learn about the implications of employing oral, non-monitored anticoagulants with clinical effects mediated by novel mechanisms of action.
  
  
• Learn to risk stratify patients, assess their likelihood for incurring stroke in the setting of AF and be aware of current and evolving prophylaxis measures that can reduce the incidence of stroke.
  

Disclaimer:

Copyright © 2010 by CMEducation Resources and Pharmatecture, LLC. All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2010 All rights reserved